Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
6.90
+0.02 (0.22%)
Mar 6, 2026, 1:23 PM EST - Market open
Kyntra Bio Employees
Kyntra Bio had 225 employees as of December 31, 2024. The number of employees decreased by 261 or -53.70% compared to the previous year.
Employees
225
Change (1Y)
-261
Growth (1Y)
-53.70%
Revenue / Employee
$36,880
Profits / Employee
$958,462
Market Cap
27.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Cue Biopharma | 41 |
| Werewolf Therapeutics | 39 |
| AN2 Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| FibroBiologics | 15 |
| Rein Therapeutics | 11 |
KYNB News
- 10 days ago - What's Going On With Kyntra Bio Stock Tuesday? - Benzinga
- 10 days ago - Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - GlobeNewsWire
- 16 days ago - Kyntra Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewsWire
- 4 months ago - FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - FibroGen to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 6 months ago - FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire